Background
==========

Genetic association studies now customarily involve multiple SNPs in candidate genes or genomic regions and have a significant role in identifying and characterizing disease-predisposing variant(s). A critical challenge in their statistical analysis is how to make optimal use of all available information. Population-based case-control studies have been very popular\[[@B1]\] and typically involve contingency table tests of SNP-disease association\[[@B2]\]. Notably, the genotype-wise Armitage trend test does not require *HWE*and has equivalent power to its allele-wise counterpart under *HWE*\[[@B3],[@B4]\]. A thorny issue with individual tests of SNPs for linkage disequilibrium (*LD*) in such setting is multiple testing, however, methods for multiple testing adjustment assuming independence such as Bonferroni\'s\[[@B5],[@B6]\] is knowingly conservative\[[@B7]\]. It is therefore necessary to seek alternative approaches which can utilize multiple SNPs simultaneously. The genotype-wise Armitage trend test is appealing since it is equivalent to the score test from logistic regression\[[@B8]\] of case-control status on dosage of disease-predisposing alleles of SNP. However, testing for the effects of multiple SNPs simultaneously via logistic regression is no cure for difficulty with multicollinearity and curse of dimensionality\[[@B9]\]. Haplotype-based methods have many desirable properties\[[@B10]\] and could possibly alleviate the problem\[[@B11]-[@B14]\], but assumption of *HWE*is usually required and a potentially large number of degrees of freedom are involved\[[@B7],[@B11],[@B15]-[@B18]\].

It has recently been proposed that *PCA*can be combined with logistic regression test (*LRT*)\[[@B7],[@B16],[@B17]\] in a unified framework so that *PCA*is conducted first to account for between-SNP correlations in a candidate region, then *LRT*is applied as a formal test for the association between *PC*scores (linear combinations of the original SNPs) and disease. Since *PC*s are orthogonal, it avoids multicollinearity and at the meantime is less computer-intensive than haplotype-based methods. Studies have shown that *PCA-LRT*is at least as powerful as genotype- and haplotype-based methods\[[@B7],[@B16],[@B17]\]. Nevertheless, the power of *PCA*-based approaches vary with ways by which *PC*s are extracted, e.g., from genotype correlation, LD, or other kinds of metrics\[[@B17]\], and in principle can be employed in frameworks other than logistic regression\[[@B7],[@B16],[@B17]\]. Here we investigate ways of extracting *PCs*using genotype correlation matrix from different types of samples in a case-control study, while presenting a new approach testing for gene-disease association by direct use of *PC*scores in a *PCA*-based bootstrap confidence interval test (*PCA-BCIT*). We evaluated its performance via simulations and compared it with *PCA-LRT*and permutation test using real data.

Methods
=======

PCA
---

Assume that *p*SNPs in a candidate region of interest have coded values (*X*~1~, *X*~2~, ⋯, *X*~*p*~) according to a given genetic model (e.g., additive model) whose correlation matrix is *C*. *PCA*solves the following equation,

where = 1, *i*= 1,2, ⋯, *p*, *l*~*i*~= (*l*~*i*1~, *l*~*i*2~, ⋯, *l*~*ip*~)\' are loadings of *PC*s. The score for an individual subject is

where cov (*F*~*i*~, *F*~*j*~) = 0, *i*≠ *j*, and var(*F*~1~) ≥ var(*F*~2~) ≥ ⋯ ≥ var(*F*~*p*~).

Methods of extracting *PC*s
---------------------------

Potentially, *PCA*can be conducted via four distinct extracting strategies (*ES*) using case-control data, i.e., 0. Calculate *PC*scores of individuals in cases and controls separately (*SES*), 1. Use cases only (*CAES*) to obtain loadings for calculation of *PC*scores for subjects in both cases and controls, 2. Use controls only (*COES*) to obtain the loadings for both groups, and 3. Use combined cases and controls (*CES*) to obtain the loadings for both groups. It is likely that in a case-control association study, loadings calculated from cases and controls can have different connotations and hence we only consider scenarios 1-3 hereafter. More formally, let (*X*~1~, *X*~2~, ⋯, *X*~*p*~) and (*Y*~1~, *Y*~2~, ⋯, *Y*~*p*~) be *p*-dimension vectors of SNPs at a given candidate region for cases and controls respectively, then we have,

Strategy 1 (***CAES***):

where *C*~*XX*~is the correlation matrix of (*X*~1~, *X*~2~, ⋯, *X*~*p*~), and = 1, *i*= 1,2, ⋯, *p*. The *i*^*th*^*PC*for cases is calculated by

and for controls

Strategy 2 (***COES***):

where *C*~*YY*~is the correlation matrix of (*Y*~1~, *Y*~2~, ⋯, *Y*~*p*~). The *i*^*th*^*PC*for controls is calculated by

And for cases, the *i*^*th*^*PC*, i = 1,2, ⋯, *p*, is calculated by

Strategy 3 (***CES***):

where *C*is the correlation matrix obtained from the pooled data of cases and controls, and . The *i*^*th*^*PC*of cases is calculated by

The *i*^*th*^*PC*of controls is calculated by

PCA-BCIT
--------

Given a sample of *N*cases and *M*controls with *p*-SNP genotypes (*X*~1~, *X*~2~, ⋯, *X*~*N*~)^*T*^, (*Y*~1~, *Y*~2~, ⋯, *Y*~*M*~)^*T*^, and *X*~*i*~= (*X*~1*i*~, *X*~2*i*~, ⋯, *x*~*pi*~) for the *i*^*th*^case, *Y*~*i*~= (*Y*~1*i*~, *Y*~2*i*~, ⋯, *y*~*pi*~) for the *i*^*th*^control, a *PCA-BCIT*is furnished in three steps:

### Step 1: Sampling

Replicate samples of cases and controls are obtained with replacement separately from (*X*~1~^(*b*^, *X*~2~^(*b*)^, ⋯, *X*~*N*~^(*b*)^)^*T*^and (*Y*~1~^(*b*^, *Y*~2~^(*b*)^, ⋯, *Y*~*M*~^(*b*)^)^*T*^, *b*= 1,2, ⋯, *B*(*B*= 1000).

### Step 2: *PCA*

For each replicate sample obtained at Step 1, *PCA*is conducted and a given number of *PC*s retained with a threshold of 80% explained variance for all three strategies\[[@B16]\], expressed as and .

### Step 3: *PCA-BCIT*

**3a**) For each replicate, the mean of the *k*^*th*^*PC*in cases is calculated by

and that of the *k*^*th*^*PC*in controls is calculated by

**3b**) Given confidence level (1 - α ), the confidence interval of is estimated by percentile method, with form

where is the percentile of , and is the percentile.

The confidence interval of is estimated by

where is the percentile of , and is the percentile.

**3c**) Confidence intervals of cases and controls are compared. The null hypothesis is rejected if and do not overlap, which is and are statistically different\[[@B19]\], indicating the candidate region is significantly associated with disease at level α. Otherwise, the candidate region is not significantly associated with disease at level α.

Simulation studies
------------------

We examine the performance of *PCA-BCIT*through simulations with data from the North American Rheumatoid Arthritis (RA) Consortium (NARAC) (868 cases and 1194 controls)\[[@B20]\], taking advantage of the fact that association between protein tyrosine phosphatase non-receptor type 22 (*PTPN22*) and the development of RA has been established\[[@B21]-[@B24]\]. Nine SNPs have been selected from the *PNPT22*region (114157960-114215857), and most of the SNPs are within the same LD block (Figure [1](#F1){ref-type="fig"}). Females are more predisposed (73.85%) and are used in our simulation to ensure homogeneity. The corresponding steps for the simulation are as follows.

![**LD (*r*^2^) among nine *PTPN22*SNPs**. The nine *PTPN22*SNPs are rs971173, rs1217390, rs878129, rs11811771, rs11102703, rs7545038, rs1503832, rs12127377, rs11485101. The triangle marks a single LD block within this region: (rs878129, rs11811771, rs11102703, rs7545038, rs1503832, rs12127377, rs11485101).](1471-2156-11-6-1){#F1}

### Step 1: Sampling

The observed genotype frequencies in the study sample are taken to be their true frequencies in populations of infinite sizes. Replicate samples of cases and controls of given size (*N*, *N*= 100, 200, ⋯, 1000) are generated whose estimated genotype frequencies are expected to be close to the true population frequencies while both the allele frequencies and *LD*structure are maintained. Under null hypothesis, replicate cases and controls are sampled with replacement from the controls. Under alternative hypothesis, replicate cases and controls are sampled with replacement from the cases and controls respectively.

### Step 2: *PCA-BCITing*

For each replicate sample, *PCA-BCITs*are conducted through the three strategies of extracting *PC*s as outlined above on association between *PC*scores and disease (RA).

### Step 3: Evaluating performance of *PCA-BCIT*s

Repeat steps 1 and 2 for *K*( *K*= 1000 ) times under both null and alternative hypotheses, and obtain the frequencies (*P*~*α*~) of rejecting null hypothesis at level α (α = 0.05).

Applications
------------

*PCA-BCITs*are applied to both the NARAC data on *PTPN22*in 1493 females (641 cases and 852 controls) described above and a data containing nine SNPs near μ-opioid receptor gene (*OPRM1*) in Han Chinese from Shanghai (91 cases and 245 controls) with endophenotype of heroin-induced positive responses on first use\[[@B25]\]. There are two LD blocks in the region of gene *OPRM1*(Figure [2](#F2){ref-type="fig"}).

![**LD (*r*^2^) among nine *OPRM1*SNPs**. The nine *OPRM1*SNPs are rs1799971, rs510769, rs696522, rs1381376, rs3778151, rs2075572, rs533586, rs550014, rs658156. The triangles mark the LD block 1 (rs696522, rs1381376, rs3778151) and LD block 2 (rs550014, rs658156).](1471-2156-11-6-2){#F2}

Results
=======

Simulation study
----------------

The performance of *PCA-BCIT*is shown in Table [1](#T1){ref-type="table"} for the three strategies given a range of sample sizes. It can be seen that strategies 2 and 3 both have type I error rates approaching the nominal level (α = 0.05), but those from strategy 1 deviate heavily. When sample size larger than 800, the power of *PCA-BCIT*is above 0.8, and strategies 2 and 3 outperform strategy 1 slightly.

###### 

Performance of *PCA-BCIT*at level 0.05 with strategies 1-3†

  Sample size   Type I error   Power                           
  ------------- -------------- ------- ------- ------- ------- -------
  100           0.014          0.036   0.037   0.156   0.163   0.176
  200           0.016          0.044   0.036   0.249   0.278   0.292
  300           0.017          0.028   0.029   0.383   0.426   0.368
  400           0.014          0.04    0.02    0.508   0.485   0.516
  500           0.009          0.035   0.042   0.613   0.595   0.597
  600           0.006          0.032   0.042   0.677   0.662   0.683
  700           0.007          0.061   0.04    0.733   0.758   0.73
  800           0.004          0.043   0.045   0.801   0.791   0.819
  900           0.005          0.057   0.051   0.826   0.855   0.858
  1000          0.01           0.056   0.05    0.871   0.901   0.889

**†**1 case-only extracting strategy (*CAES*), 2 control-only extracting strategy (*COES*), 3 case-control extracting strategy (*CES*)

Applications
------------

For the NARAC data, Armitage trend test reveals none of the SNPs in significant association with RA using Bonferroni correction (Table [2](#T2){ref-type="table"}), but the results of *PCA-BCIT*with strategies 2 and 3 show that the first *PC*extracted in region of *PTPN22*is significantly associated with RA. The results are similar to that from permutation test (Table [3](#T3){ref-type="table"}).

###### 

Armitage trend test on nine *PTPN2*2 SNPs and RA susceptibility

  SNP          Genotype   Female   Male                       
  ------------ ---------- -------- ------ ------- ----- ----- -------
  rs971173     CC         334      381    0.025   116   169   0.779
               AC         236      363            85    134   
               AA         71       106            26    39    
  rs1217390    AA         268      319    0.333   99    112   0.108
               AG         272      392            89    175   
               GG         98       138            38    55    
  rs878129     GG         338      507    0.009   131   187   0.384
               AG         251      291            83    130   
               AA         52       54             13    25    
  rs11811771   AA         224      272    0.090   78    111   0.717
               AG         303      411            104   168   
               GG         112      169            45    62    
  rs11102703   CC         312      469    0.024   121   174   0.418
               AC         269      314            90    137   
               AA         60       69             16    31    
  rs7545038    GG         321      428    0.696   109   186   0.417
               AG         265      342            98    114   
               AA         52       80             20    40    
  rs1503832    AA         324      487    0.013   129   185   0.249
               AG         262      306            86    127   
               GG         55       59             12    30    
  rs12127377   AA         349      521    0.017   139   197   0.230
               AG         243      282            78    121   
               GG         49       48             10    24    
  rs11485101   AA         564      738    0.656   206   305   0.430
               AG         72       112            21    35    
               GG         5        2              0     2     

None of the P-values is significant after Bonferroni Correction.

###### 

*PCA-BCIT*, *PCA-LRT*and permutation test on real data

  ---------------------------------------------------------------------------------------------------
  Study      Strategy†   *99%CI*                    *95%CI*                  *P*-value‡   
  ---------- ----------- -------------------------- ------------------------ ------------ -----------
  *PTPN22*   *2*         (-5.4E-01,-4.7E-03)\*\*\   (-4.8E-01,-8.6E-02)\*\   0.006\*\*    0.002\*\*
                         (-7.5E-16,6.9E-16)         (-4.6E-16,4.2E-16)                    

             *3*         (1.7E-02,3.3E-01)\*\*\     (4.9E-02,3.0E-01)\*\     0.007\*\*    0.002\*\*
                         (-2.5E-01,-1.3E-02)        (-2.2E-01,-3.7E-02)                   

  *OPRM1*    *2*         (-1.2E+00,-1.1E-02)\*\*\   (-1.1E+00,-1.8E-01)\*\   0.107        0.002\*\*
                         (-4.7E-16,5.0E-16)         (-3.7E-16,3.4E-16)                    

             *3*         (5.3E-02,1.4E+00)\*\*\     (2.4E-01,1.2E+00)\*\     0.012\*      0.004\*\*
                         (-4.9E-01,-1.7E-02)        (-4.2E-01,-8.0E-02)                   
  ---------------------------------------------------------------------------------------------------

**†**2 control-only extracting strategy (*COES*), 3 case-control extracting strategy (*CES*)

‡\* significant at levels α = 0.05(\*) and α = 0.01 (\*\*).

For the *OPRM1*data, the sample characteristics are comparable between cases and controls (Table [4](#T4){ref-type="table"}), and three SNPs (rs696522, rs1381376 and rs3778151) are showed significant association with the endophenotype (Table [5](#T5){ref-type="table"}). The results of *PCA-BCIT*with strategies 2 and 3 and permutation test are all significant at level α = 0.01. In contrast, result from *PCA-LRT*is not significant at level α = 0.05 with strategy 2 (Table [3](#T3){ref-type="table"}). The apparent separation of cases and controls are shown in Figure [3](#F3){ref-type="fig"} for *PCA-BCIT*with strategy 3, suggesting an intuitive interpretation.

###### 

Sample characteristics of heroin-induced positive responses on first use

                                   Cases (*N*= 91)   Controls (*N*= 245)   *P*-value
  -------------------------------- ----------------- --------------------- -----------
  Age (yrs)                        30.42 ± 7.65      30.93 ± 8.18          0.6057
  Women (%)                        26.4              29.8                  0.5384
  Age at onset (yrs)               26.29 ± 7.41      26.97 ± 7.89          0.4760
  Reason for first use of heroin                                           0.7173
  Curiousness                      79.1              75.1                  
  Peer pressure                    6.6               4.9                   
  Physical disease                 7.7               10.2                  
  Trouble                          5.5               6.1                   
  Other reasons                    1.1               3.8                   

###### 

Armitage trend tests on nine *OPRM1*SNPs and heroin-induced positive responses on first use

  SNP         Genotype   Count and frequency   Armitage trend test                          
  ----------- ---------- --------------------- --------------------- ----- ------- -------- ----------
  rs1799971   AA         55                    0.604                 150   0.622   0.003    0.9537
              AG         27                    0.297                 64    0.266            
              GG         9                     0.099                 24    0.112            
  rs510769    TT         56                    0.667                 167   0.749   2.744    0.0976
              TC         24                    0.286                 53    0.237            
              CC         4                     0.048                 4     0.018            
  rs696522    AA         64                    0.762                 215   0.907   11.097   0.0009\*
              AG         19                    0.226                 21    0.089            
              GG         1                     0.012                 1     0.004            
  rs1381376   CC         70                    0.769                 221   0.913   13.409   0.0003\*
              CT         20                    0.220                 21    0.087            
              TT         1                     0.011                 0     0.000            
  rs3778151   GG         66                    0.733                 215   0.896   14.655   0.0001\*
              GA         23                    0.256                 25    0.104            
              AA         1                     0.011                 0     0.000            
  rs2075572   GG         50                    0.556                 149   0.642   1.574    0.2096
              GC         33                    0.367                 82    0.353            
              CC         7                     0.078                 11    0.047            
  rs533586    TT         68                    0.840                 203   0.868   0.761    0.3830
              TC         12                    0.148                 31    0.132            
              CC         1                     0.012                 0     0.000            
  rs550014    TT         78                    0.857                 203   0.832   0.093    0.7602
              TC         12                    0.132                 41    0.168            
              CC         1                     0.011                 0     0.000            
  rs658156    GG         65                    0.714                 192   0.787   2.041    0.1531
              GA         24                    0.264                 52    0.213            
              AA         1                     0.011                 0     0.000            

\* significant after Bonferroni Correction.

![**Real data analyses by *PCA-BCIT*with strategy 3 and confidence level 0.95**. The horizontal axis denotes studies and vertical axis *mean(PC1)*, the statistic used to calculate confidence intervals for cases and controls. *PCA-BCIT*s with strategy 3 were significant at confidence level 0.95.](1471-2156-11-6-3){#F3}

Discussion
==========

In this study, a *PCA*-based bootstrap confidence interval test\[[@B19],[@B26]-[@B28]\] (*PCA*-*BCIT*) is developed to study gene-disease association using all SNPs genotyped in a given region. There are several attractive features of *PCA*-based approaches. First of all, they are at least as powerful as genotype- and haplotype-based methods\[[@B7],[@B16],[@B17]\]. Secondly, they are able to capture LD information between correlated SNPs and easy to compute with needless consideration of multicollinearity and multiple testing. Thirdly, *BCIT*integrates point estimation and hypothesis testing as a single inferential statement of great intuitive appeal\[[@B29]\] and does not rely on the distributional assumption of the statistic used to calculate confidence interval\[[@B19],[@B26]-[@B29]\].

While there have been several different but closely related forms of bootstrap confidence interval calculations\[[@B28]\], we focus on percentiles of the asymptotic distribution of *PC*s for given confidence levels to estimate the confidence interval. *PCA-BCIT*is a data-learning method\[[@B29]\], and shown to be valid and powerful for sufficiently large number of replicates in our study. Our investigation involving three strategies of extracting *PC*s reveals that strategy 1 is invalid, while strategies 2 and 3 are acceptable. From analyses of real data we find that *PCA-BCIT*is more favourable compared with *PCA-LRT*and permutation test. It is suggested that a practical advantage of *PCA-BCIT*is that it offers an intuitive measure of difference between cases and controls by using the set of SNPs (*PC*scores) in a candidate region (Figure [3](#F3){ref-type="fig"}). As extraction of *PC*s through *COES*is more in line with the principle of a case-control study, it will be our method of choice given that it has a comparable performance with *CES*. Nevertheless, *PCA-BCIT*has the limitation that it does not directly handle covariates as is usually done in a regression model.

Conclusions
===========

*PCA-BCIT*is both a valid and a powerful *PCA*-based method which captures multi-SNP information in study of gene-disease association. While extracting *PC*s based on *CAES, COES*and *CES*all have good performances, it appears that *COES*is more appropriate to use.
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